Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Immunotherapy
•
Renal Cell Carcinoma
•
NCI-CCC Tumor Board Question
•
Duke
•
NCI-CCC GU Tumor Board Question
In a patient with metastatic RCC who discontinued nivolumab after a prolonged response to ipilimumab/nivolumab, would you consider re-starting nivolumab at disease progression?
Related Questions
Would you extrapolate from EMBARK to use an ARPI other than enzalutamide in high risk biochemically recurrent prostate cancer for a patient with contraindications to enzalutamide?
What is the optimal approach to systemic therapy for metastatic squamous cell carcinoma of the bladder considering the approval of enfortumab vedotin plus pembrolizumab for metastatic urothelial carcinoma?
Is there still a role for mTOR inhibitors in metastatic RCC in the immunotherapy/TKI era?
What adjuvant therapy, if any, is best for mucinous tubular and spindle cell carcinoma of the kidney?
How would you treat a patient with metastatic RCC with high grade neuroendocrine and sarcomatoid features after progression on IO + TKI?
How would you approach adjuvant systemic therapy for an isolated, oligometastatic CNS recurrence of RCC that was treated with SBRT?
Do you routinely continue patients on anti-PD(L)-1 beyond 2 years of treatment while on IO/TKI for metastatic ccRCC?
Would the occurrence of obvious tumor rupture/spillage intraoperatively impact your decision for adjuvant systemic therapy after resection of either clear cell RCC or papillary RCC?
How would you approach the use of bevacizumab in metastatic FH-deficient RCC/HLRCC that is c/b extensive IVC tumor thrombus and DVT/PE?
What is your approach to surveillance in patients with no evidence of disease after treatment of oligometastatic renal cell carcinoma?